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Abstract
Background: Chronic kidney disease (CKD) is a relatively newly recognised but common long-
term condition affecting 5 to 10% of the population. Effective management of CKD, with emphasis
on strict blood pressure (BP) control, reduces cardiovascular risk and slows the progression of
CKD. There is currently an unprecedented rise in referral to specialist renal services, which are
often located in tertiary centres, inconvenient for patients, and wasteful of resources. National and
international CKD guidelines include quality targets for primary care. However, there have been
no rigorous evaluations of strategies to implement these guidelines. This study aims to test whether
quality improvement interventions improve primary care management of elevated BP in CKD,
reduce cardiovascular risk, and slow renal disease progression
Design: Cluster randomised controlled trial (CRT)
Methods:  This three-armed CRT compares two well-established quality improvement
interventions with usual practice. The two interventions comprise: provision of clinical practice
guidelines with prompts and audit-based education.
The study population will be all individuals with CKD from general practices in eight localities
across England. Randomisation will take place at the level of the general practices. The intended
sample (three arms of 25 practices) powers the study to detect a 3 mmHg difference in systolic BP
between the different quality improvement interventions. An additional 10 practices per arm will
receive a questionnaire to measure any change in confidence in managing CKD. Follow up will take
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place over two years. Outcomes will be measured using anonymised routinely collected data
extracted from practice computer systems. Our primary outcome measure will be reduction of
systolic BP in people with CKD and hypertension at two years. Secondary outcomes will include
biomedical outcomes and markers of quality, including practitioner confidence in managing CKD.
A small group of practices (n = 4) will take part in an in-depth process evaluation. We will use time
series data to examine the natural history of CKD in the community. Finally, we will conduct an
economic evaluation based on a comparison of the cost effectiveness of each intervention.
Clinical Trials Registration: ISRCTN56023731. ClinicalTrials.gov identifier.
Background
Chronic kidney disease (CKD) is a common long-term
condition, affecting 5 to 10% of the population. CKD is
an independent risk factor for cardiovascular disease,
established renal failure (ERF) and all cause mortality [1-
3]. Patients with CKD are far more likely to die prema-
turely from cardiovascular disease than progress to ERF
requiring dialysis or transplantation. The presence of pro-
teinuria confers additional cardiovascular risk.
CKD is classified into five stages based upon a measure-
ment of kidney function and the estimated glomerular fil-
tration rate (eGFR) determines the class of CKD for the
more severe stages (Stage three to five). Stage one and two
are the mildest of the five stages of CKD and require evi-
dence of kidney damage, usually the presence of proteinu-
ria, to confirm the diagnosis. Stages three to five CKD can
be diagnosed by eGFR alone; and stage three is now often
split into stages 3a and 3b, as there are far higher rates of
cardiovascular co-morbidity in stage 3b disease. People
with cardiovascular co-morbidities especially hyperten-
sion and diabetes; cardiovascular risk factors, particularly
raised systolic blood pressure (BP); and more specific ren-
ovascular risk factors: proteinuria and anaemia are at
increased risk.
There is a broad and evidence-informed consensus that
lowering BP is of central importance, both to slow the
progression of CKD and reduce cardiovascular risk. Low-
ering of BP using angiotensin modulating anti-hyperten-
sives, angiotensin converting enzyme inhibitors (ACEI)
and angiotensin (II) receptor blockers (ARB) appears to
have additive renal-protective benefits [4]. Strict manage-
ment of BP, cardiovascular and specific renovascular risk
should be feasible in primary care. Guidelines on the
management of CKD have recently been published by the
National Institute for Health and Clinical Excellence
(NICE) [4]. In the absence of proteinuria, the threshold
for intervention is a BP of ≥ 140/90 mmHg is recom-
mended, with a target systolic BP of between 130 and 139
mmHg. In diabetes and where significant proteinuria is
present, the respective values are 130/80 mmHg with a
systolic target of between 120 and 129 mmHg. However
these targets frequently remain unmet. Studies have dem-
onstrated a need to improve both information and train-
ing available to practitioners with the aim of enabling
them to improve the quality of care currently provided
[5].
There is limited knowledge and experience of managing
this condition in primary care, and while CKD has been
included as one of the financially incentivised chronic dis-
ease management targets for general practice – the 'Qual-
ity and Outcomes Framework' (QOF) it is the only QOF
indicator to be accompanied by a 'Frequently Asked Ques-
tions' document – requested by the British Medical Asso-
ciation as a condition for the inclusion of this indicator in
the QOF indicator set [6]. Feedback to the investigators
has been that practitioners lack confidence in the manage-
ment of this condition, especially implementing the BP
targets in elderly patients (who are at higher risk of CKD
and its sequelae).
There are further problems with the QOF. The use of rou-
tinely collected clinical data for purposes other than clin-
ical care may distort data recording [7]. Practitioners feel
reluctant to include a patient with incomplete data on a
QOF disease register as this might affect their income.
Regardless, the prevalence of CKD reported through the
QOF to the NHS Information Centre for 2006/7 [8] is less
than half that reported in the epidemiological studies
quoted in this introduction. There is de facto a quality gap
as those people with CKD not on the disease register will
not be recalled for BP and other checks.
Finally, the new NICE guidance looks at CKD at a point in
time [4]. Management is largely determined by the eGFR
over a three-month period, BP control and the presence or
absence of proteinuria. Although there is a heuristic for a
rate of decline that would trigger referral, there is disso-
nance between this heuristic and clinical practice in pri-
mary care. Many elderly people with CKD, even more
advanced stage four disease, appear to be stable and the
NICE along with previous guidance may be over aggres-
sive for this group of patients; this may be part of the rea-
son why clinicians are not implementing recommendedImplementation Science 2009, 4:39 http://www.implementationscience.com/content/4/1/39
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BP targets [9,10]. Further research is needed to understand
the natural history of the disease and whether rate of
decline would be a more appropriate primary variable to
detect people at risk.
The quality of general practice computer data
UK general practice is almost universally computerised
and has some of the most advanced general practice com-
puting [11,12]; providing a rationale for the use of rou-
tinely collected data to measure the impact of the quality
improvement interventions being developed and tested in
this programme of research. Six factors contribute to the
high quality of general practice computer data: we have an
accurate denominator [13]; prescribing records are largely
complete; electronic connections to laboratories mean
that pathology data are complete; the QOF has improved
data quality in CKD and its cardiovascular co-morbidities
including diabetes; an electronic referral system has
improved data quality; and the NHS has sponsored the
development of a tool called MIQUEST (Morbidity Infor-
mation Query and Export Syntax) to extract anonymised
data – a tool we have over 10 years experience of using
[14,15].
Optimal management of CKD in primary care is currently
limited by a lack of knowledge about how to increase
adherence to guidelines for best practice [16]. There is no
single perfect quality improvement strategy to use in pri-
mary care [17]. The most commonly used strategy is dis-
semination of clinical practice guidelines with prompts
[18]. This usually involves distribution of paper guidance
and reminders with internet resources providing addi-
tional information and support. More expensive and
complex interventions have been widely used, including
audit-based education (ABE) where practitioners compare
their own practice's adherence to guidance with that of
peer practices [19,20]. Our experience from observational
work has been that ABE is more effective in its second year
[21]; a similar pattern is seen with using feedback to
improve data quality [22].
Methods
Study aims and objectives
This study aims to improve the quality of CKD manage-
ment in primary care with the emphasis on strict control
of systolic BP to reduce cardiovascular risk and slow renal
progression.
Objectives
1. To lower the BP of hypertensive individuals with CKD
to an agreed target.
2. To measure the impact of the quality improvement
interventions on the recording and control of renovascu-
lar risk factors, including proteinuria; and cardiovascular
co-morbidities, including diabetes mellitus.
3. To evaluate the quality improvement interventions and
measure their impact on other markers of quality, includ-
ing practitioner confidence.
4. To establish a cost model for each quality improvement
intervention.
5. To characterise the natural history of CKD. We wish to
compare those who have progressive (as defined by a
yearly decrease in eGFR of >5 ml/min/1.73 m2 in one year
or >10 ml/min/1.73 m2 in 5 years) [4], compared with
non-progressive renal disease; comparing demographics,
co-morbidities (including diabetes), and biomedical vari-
ables.
6. To develop improved primary care guidelines for man-
agement of CKD and measure adherence to this guidance;
with an emphasis on comparing progressive, with non-
progressive CKD.
Study design
Study design overview
We plan to conduct a two-year, three-arm cluster ran-
domised trial. We are carrying out a cluster randomised
trial because we feel that quality improvement is often
adopted at the level of the practice. A trial of individual
patients would be much more difficult because it may be
impossible to stop contamination between general practi-
tioners (GPs) and other health professionals working in
the same practice; GPs may see successive patients from
different arms of the trial; and communication between
patients randomised to different arms of the trial might
also bias results.
The study has two components: a core cluster randomised
trial (CRT) of 75 practices, and a parallel process evalua-
tion and measure of how GP confidence changes over
time. The core study is a three-arm CRT of 75 practices.
These 75 practices are randomised into three arms of 25
practices comparing usual practice, guidelines and
prompts (GaP), and ABE. This sample size is needed to
show a difference of 3 mmHg in systolic BP (Figure 1).
There is also a parallel study that contains additional prac-
tices: four practices form our in-depth process evaluation
practices, and two testing each active intervention. Addi-
tionally, 10 practices in each arm of the study will com-
plete a confidence questionnaire to assess if/how
practitioner confidence changes in the different arms of
the study (Figure 2).
However, the parallel study (Figure 2) contains two other
elements:Implementation Science 2009, 4:39 http://www.implementationscience.com/content/4/1/39
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1. Four in-depth process evaluation practices: These
practices will take part in our diagnostic analysis proc-
ess at the start of the study proper (i.e., does the inter-
vention meet their perceived needs, and does it
address barriers to quality improvement). They will
validate our questionnaire to assess confidence and,
during the study proper, report on the intervention
exposure (i.e., to what extent the intended recipients
are exposed to the interventions); and programme
fidelity (i.e., whether the quality improvement inter-
vention is delivered as planned). Two practices will
give in-depth feedback about the GaP intervention
and two about ABE. We will use focus groups run in
each practice as our principal method of data collec-
tion; however we also plan a mid-study workshop of
all the in-depth process evaluation practices. Our sam-
ple will include at least one practice from the north
and from the south; we intend to recruit inner city,
suburban, and county town practices; we want to see
the four major brands of general practice computer
systems represented across the practices so that we can
also test our queries and data extracts.
2. An additional 10 practices in each arm will com-
plete a confidence questionnaire: We will recruit 10
additional practices in each arm that will participate in
the study but also complete a questionnaire about
their confidence in the management of CKD. We are
primarily doing this to assess if any of the interven-
tions have a greater effect on confidence. We are send-
ing this questionnaire to a separate group of practices
because completing the questionnaire may be an
intervention in its own right, possibly as great as GaP.
We will be able to compare questionnaire and non-
questionnaire practices in each arm at the end of the
study.
Participants
The participants are GPs located in practices (our clusters)
across England. We aim to recruit a nationally representa-
tive sample of practices from: in and around London –
especially inner city and suburban southwest London;
urban and rural Surrey and Sussex; Leicester city and sur-
rounding areas; Birmingham inner city and suburban;
and Cambridge. The locality structure is pragmatic
because groups of practices need to come together for the
ABE workshops. An inclusion criteria for a locality is that
their local renal unit would support the workshop within
their locality and review the GaP to minimise any conflict
with local policy.
The primary research participants are GPs involved in the
study who will receive the quality improvement interven-
tions listed below. The interventions will be implemented
at the practice (cluster) rather than the individual level.
The study subjects (who may be regarded as secondary
participants) will be all individuals with CKD within the
study practices. CKD will be defined using the interna-
tionally accepted National Kidney Foundation (NKF) def-
inition [23] using two measures of eGFR of less than 60
ml/min/1.73 m2 at least three months apart. However, we
will also explore the effects of including people with a sin-
gle recording of eGFR.
The participants do not receive any financial incentives to
participate, though they do receive financial compensa-
tion for the time actually spent attending study activities.
These will vary according to the arm of the study they are
allocated to.
The core study sample: a three-arm cluster randomised trial  comparing Usual practice with Guidelines and Prompts (GaP)  and Audit-based Education (ABE) Figure 1
The core study sample: a three-arm cluster ran-
domised trial comparing Usual practice with Guide-
lines and Prompts (GaP) and Audit-based Education 
(ABE).
Randomisation at practice level at start of year one 
Audit-based 
education 
n = 25 practices 
Usual practice 
n = 25 practices 
Guidelines and 
prompts 
n = 25 practices 
n = 75 practices 
Registered population § 500,000 
CKD patients § 36,000 
The greater study contains the core CRT with 25 practices in  each arm Figure 2
The greater study contains the core CRT with 25 
practices in each arm. In addition there are 10 confidence 
questionnaire practices per arm and two in-depth process 
analysis practices in each of the active study arms.
 
 
 
n = 105 practices 
(1) Core CRT = 75 practices 
(2) Confidence questionnaire = 30 practices 
Guidelines + prompts
n = 35 practices 
1) Core CRT = 25 
(2) Questionnaire = 10 
Randomisation at practice level at start of year 1 
Audit-based education 
n = 35 practices 
1) Core CRT = 25 
(2) Questionnaire = 10 
N= 4 practices 
In-depth process 
evaluation 
Usual practice 
n = 35 practices 
(1) Core CRT = 25 
(2) Questionnaire = 10 
Guidelines + prompts 
N = 2 practices 
Process data only
Purposive sample 
Audit based education 
N = 2 practices 
Process data onlyImplementation Science 2009, 4:39 http://www.implementationscience.com/content/4/1/39
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Inclusion and exclusion criteria
Inclusion criteria
1. Localities require the local renal unit to share local
guidance and support our interventions.
2. Primary care organisation approval for the research to
be conducted in their locality.
3. Practices who provide written consent to participate.
4. Agreement to participate in whichever arm of the study
they are randomly allocated.
5. Practice has had the same computer system for the last
five years and has no plans to change it, and will allow
access to check data quality.
6. Practice has electronic laboratory links for three years or
more.
Exclusion criteria
1. Practices in whom the computing system has changed
over the last five years.
2. Practices lacking an appropriate computer system from
which data can be extracted.
3. Practices in which referral data (from primary care to
secondary care) is not available.
4. Practices planning to move computer system in the next
two years.
Recruitment
Dedicated members of the study team (NT and NJ) liaise
with and recruit eligible practices from the study's 'locali-
ties' who meet with the above inclusion criteria. The pri-
mary care research networks, funded by the National
Institute for Health Research (NIHR) have actively sup-
ported the recruitment for the study in all of our target
areas since the project was added to the NIHR portfolio of
research projects. Recruitment has also been carried out
by writing to practices associated with teaching networks
in southwest London, Surrey and Sussex (SdeL). There has
been word-of-mouth recruitment from members of the
project team, and snowball recruitment from practice to
practice.
Consent
Practices will be asked to consent as a unit, with all GPs
being willing to participate. One or more persons will sign
the consent form as authorised by the practice. This may
vary from all GPs to one GP being authorised to consent
on behalf of the practice. No direct consent is taken from
patients, however a waiting room poster is provided as
well as a lay summary of the project in leaflet form.
Interventions
The interventions in the study
Two interventions are being compared to usual practice:
GaP and ABE. The interventions are designed to target the
cluster (i.e., individual general practices). Where we send
GaP or questionnaires we send them to individual named
clinicians. Where a practice is invited to attend an ABE
workshop all members may attend; however, our experi-
ence is that one or more practice members attend on
behalf of the others; we try to compensate for this by pro-
viding learning resources for them to take back to their
practices. However, although we send some material to
individuals, the intervention is focused at the level of the
practice.
Usual practice
These practices will be allocated to this arm at randomisa-
tion (n = 35 practices – 25 in the core CRT and 10 in the
questionnaire group). Once assigned to this arm, a mini-
mum of contacts will be made of these practices other
than for data collection.
Distribution of clinical practice guidelines with prompts (GaP)
This is an established, low cost method of quality
improvement [17]. It will provide a benchmark with
which the effectiveness of the other quality improvement
intervention can be compared. We will develop a consen-
sus between the study team, our expert advisory group,
and external peer reviewers, and produce appropriate
guidance for the management of CKD in primary care.
This guidance will be distributed to practices within this
arm of the CRT (n = 25 practices plus 10 questionnaire
practices) with six monthly updates and reminders. The
guidance will be customised to fit with local practice and
reflect guidance in that area. In addition practices will
have access to a supportive website with information
about CKD, frequently asked questions, and tools to
improve CKD management.
The GaP documentation will typically be up to four sides
of A4 paper stock, published in a glossy professionally
printed form. It may be accompanied by local guidance or
national brief guidance in the first intervention. We plan
to distribute the NICE 'Quick Reference Guide' to manag-
ing CKD [24] as part of the second-year intervention.
Audit based-education (ABE)
In this arm, practices (n = 25 practices plus 10 question-
naire practices) will have a representative attend work-
shops. These practices will also have access to clinical
practice guidelines provided to the second arm of the
study. However, in addition, practices will receive threeImplementation Science 2009, 4:39 http://www.implementationscience.com/content/4/1/39
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sets of detailed comparative feedback about their quality
of CKD management at approximately nine-month inter-
vals, and we will facilitate lists of patients needing inter-
ventions (local queries) being created within the practice.
This comparative feedback about adherence to guidelines
will be based on anonymised data collected from their
general practice computer system prior to the ABE work-
shop.
The study will use an ABE model for quality improvement
developed by the primary care data quality project that
has been used in a variety of clinical contexts [19]. This
involves feedback given in a workshop setting with at least
one GP and one nurse or practice manager from each
practice present. The workshops will be in two parts: the
first will be facilitated by a GP familiar with the data, ide-
ally from the locality, but if not, available from study
team, and a local renal specialist in attendance to provide
expert advice and information about local practice. The
first part will be a presentation of the comparative adher-
ence to evidence-based guidance for the management of
CKD by the different practices present led by the GP. This
section will highlight variation in the quality of care in a
non-judgemental context. The second part of the meeting
will be case studies, facilitated by the local consultant,
which small groups will work through to explore dilem-
mas in management and how to overcome them.
The workshops are timetabled for two and a half hours of
activity with additional break time to allow informal con-
tact. Practices are expected to bring along at least one GP
and one or two other members of the practice team: their
practice manager and a nurse involved in cardiovascular
risk assessment or diabetes within the practice.
Delegates are asked to fill in a feedback form, of the stand-
ard type used to evaluate educational meetings, on the
usefulness and appropriateness of the content and the
educational methods used. There is also the opportunity
to provide informal feedback. This feedback, along with a
narrative from the three members of the study team who
participate in these workshops (it is expected there will be
at least three) will be fed back into the design of subse-
quent feedback. Semi-structured interviews – reviewing
the appropriateness of the level; the content and the deliv-
ery are being held in person or by telephone with all
members of the study team who had attended or partici-
pated in the first round of workshops.
The content of the interventions
The content and focus of the GaP arms of the study will be
the same as in the ABE arm. The areas and learning objec-
tives for each year have been set; however, the specific
details will depend on the national guidance available at
the time. Currently, we are basing our year one criteria
and standards on the NICE guidance released in Septem-
ber 2008 [4].
Year one
During the first year, the clinical focus will be on under-
standing any gap between the 'true' prevalence revealed by
the audit and the 'QOF prevalence' the practice reported
to the NHS Information Centre, which is publicly availa-
ble information [8]. We expect our audit to identify
approximately double the number of people with CKD
than included in the practice QOF disease register. In
addition, this year will look at proteinuria recording, con-
trol of BP and use of appropriate therapy: angiotensin
modulating drugs, appendix 1.
Year two
The second year's clinical focus will be on the manage-
ment of co-morbidities, especially diabetes. Strict control
of cardiovascular risk factors in patients with CKD and
Cardiovascular System (CVS) risk is important. We also
look at control of BP in diabetes. People with diabetes and
CKD need stricter BP control, especially if they have
microalbuminuria; diabetics are also one of the most
likely groups to go on to require renal replacement ther-
apy, appendix 2.
Outcome measures
Our primary care outcome measure is change in systolic
BP in people with hypertension and stage three to five
CKD. We have secondary outcome measured in the fol-
lowing categories:
1. What happened: Clinical outcomes and change in prac-
titioner confidence.
2. Why change happened: Diagnostic analysis plus proc-
ess evaluation.
3. What it cost: Economic evaluation.
4. Unexpected consequences.
Primary outcome measure
The primary outcome measure is the reduction of systolic
BP in hypertensive people with Stage three to five CKD
towards the current national target [4]. [Hypertension is
defined as above >140 mmHg in low-risk patients and
>130 mmHg in high-risk patients. High-risk patients are
people with CKD plus significant proteinuria (ACR ≥ 70
mg/mmol; or equivalent) or with CKD and diabetes.
We plan to measure the effect of the intervention across
the same cohort, though we recognise that it will have less
effect on people in stage four and five CKD, as these peo-
ple are largely managed by specialists. However, as theyImplementation Science 2009, 4:39 http://www.implementationscience.com/content/4/1/39
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represent a small percentage of the people with stage three
to five disease (<5%) [5], we think this is unlikely to sig-
nificantly distort our results. We will also explore the
effect of the intervention on people older than 75 years.
Secondary outcome measures
In addition to measuring the effect of the various quality
interventions upon systolic BP, will study a number of sec-
ondary outcomes:
Clinical and laboratory markers
1. Case definition using eGFR: We will define cases using
the internationally accepted definition used by NKF Kid-
ney Disease Outcomes Quality Initiative (KDOQI) [23],
the same definition is used by NICE [4]. We will identify
cases recorded since the standardisation of creatinine
recording in 2006. However, we will also undertake a sen-
sitivity analysis, including how prevalence changes when
the date or number of readings are changed.
2. BP: We will measure the proportion of people in each
arm with hypertension and CKD who achieve at least a ≥
5 mmHg reduction in systolic BP. The reduction of mean
systolic BP (the primary outcome measures) could be dis-
torted in a number of ways.
3. Recording and management of key co-morbidities: dia-
betes and its complications; ischaemic heart disease; heart
failure; obstruction/lower urinary tract symptoms.
4. Recording and management of other cardiovascular
risk factors: smoking status; lipid management; proteinu-
ria; anaemia; glycated haemoglobin and microalbuminu-
ria in people with diabetes.
5. Serial measures of serum creatinine concentration and
eGFR: to explore natural history and look for cases of
accelerated decline (defined as a reduction of eGFR of >5
ml/min/1.73 m2 in one year; or >10 ml/min/1. 73 m2 in
five years) [4].
6. Recording of death and cause of death: Although this is
incompletely recorded, we will attempt to capture any
recording as we expect mortality among hypertensive peo-
ple over the period of the study. There may be a higher
mortality among those who are in the control than inter-
vention arms.
7. Avoiding harm: We wish to monitor whether BP reduc-
tion is associated with an increased number of falls partic-
ularly in older people. Most people with CKD are elderly
and at potential risk for falls. Notwithstanding the results
of recent systematic reviews that failed to show an associ-
ation between falls and anti-hypertensive medication
[25,26], this remains a genuine concern to some practi-
tioners, and one that we propose to examine. A falls data-
set will be devised and integrated into the renal dataset.
We will investigate the relationship with use of ACE inhib-
itors and angiotensin II receptor blockers and systolic BP
below 120 in CKD.
8. Medicines management
8. a. Use of drugs/therapy that affect renal function (for
example non-steroidal anti-inflammatory drugs)
8. b. Use of ACEI and angiotensin II receptor blockers to
control hypertension
8. c. Recording of medicines possession ratio based on
days prescribed therapy as an index of concordance with
anti-hypertensive therapy.
The details of our dataset are shown in appendix 3.
Diagnostic analysis and process evaluation, including 
confidence and end of project questionnaires
1. Practitioner confidence to be measured at t = 0, t = 18
months using a questionnaire that assesses confidence.
2. Feedback from focus groups held prior to round one
(diagnostic analysis).
3. Feedback from focus groups held mid-study and at the
end of the study.
4. End of study questionnaire and workshops.
Economic evaluation
We know the economic impact of implementing guidance
in place prior to the publication of NICE guidance in Sep-
tember 2008 for the primary care management of CKD
[27]. We will update the model used by Klebe et al. to
reflect the restriction of investigations for renal bone dis-
ease in current guidance [4] compared with those advo-
cated in previous guidance [28]. We will then compare the
projected investigation cost with the true costs as repre-
sented in the routinely collected data.
Unexpected consequences
We wish to capture any unintended consequences
through our process evaluation arm, especially via the
open questions in each year of the study (appendices 1
and 2). Many implementations of IT-based change have
unintended consequences [29]. Specifically, we will
explore with process improvement practices any issues
about calling in or recalling patients, and any adverse
reactions to therapy or interactions; we will also look at
the rates of collection of prescriptions for ACEI and ARB
as a proxy for medicine possession ratio. Quality improve-Implementation Science 2009, 4:39 http://www.implementationscience.com/content/4/1/39
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ment strategies based on open sharing of data may also
have unintended consequences [30-32]; though in this
study our data sharing is largely within the peer group
rather than with the public.
Data quality assurance
The study has been designed and will be reported in
accordance with the CONSORT (Consolidated Statement
of Reporting Trials) and its extension to cluster ran-
domised trials [33]. Data will be controlled in accordance
with data protection legislation, institutional protocols of
St. George's University of London, and NHS policies for
research and information governance for ensuring patient
confidentiality [34]. Data will be analysed in SPSS (Statis-
tical Package for Social Sciences) version 15 using an
intention to treat approach.
Biomedical data
These data will be extracted from general practice compu-
ter systems using the department of health sponsored data
extraction system MIQUEST. MIQUEST has been devel-
oped by the NHS and is used in the national data quality
programme at PRIMIS (Primary Care Information Serv-
ices) [35]. This application allows identical searches on
different brands of general practice computer systems.
MIQUEST, when written in its 'remote' mode, extracts
pseudo-anonymised clinical data. In its 'local' mode, it
allows the extraction of patient identifiable data, such as
postcodes for mapping onto multiple deprivation index,
and for case-finding within the practice.
Routinely collected general practice computer data are
complex and require significant processing and interpre-
tation in order to obtain meaningful information [36].
The research team has considerable experience and has
developed a published method [37]. The research data
will be completely traceable due to the development of a
sophisticated meta-data schema [38,29]. Our extraction
technique includes thorough piloting and planning, and
data processing with quality controls at each stage. All var-
iables are examined for their distribution, and cleaned
appropriately. Where possible, we use therapy and/or
pathology tests to triangulate diagnostic and symptom
codes.
An issue with routine data is that they are incomplete, and
in contrast with other trial data are not systematically
recorded at regular intervals. However, we expect to have
relatively complete data on people with cardiovascular co-
morbidity for the last five years (since the 2004 new con-
tract for general practice) and hopefully longer. The qual-
ity of UK primary care data continues to increase, and
there is a growing amount of published research that is
based on routinely collected data – especially from coun-
tries with registration based primary care [14].
We have an agreement with CKD researchers in Galway,
Ireland, who have experience of using routinely collected
data to research CKD [39,40], that they will independ-
ently scrutinise our analysis procedures and generation of
results tables.
Diagnostic analysis and process evaluation
The questionnaire to test practitioner confidence has been
developed using a standard questionnaire development
method [41]. This questionnaire, developed by GP experts
and renal specialists, has been validated through initial
testing within the study team, then tested within a south
London practitioners group who are not participants in
this study. Finally, it was tested within our process evalu-
ation group. The questionnaires are sent to individual
health care professionals participating in this study; they
are numbered so that reminders can be sent and survey
data at the different time points can be inked. Reminders
are sent by post. There will also be a final reminder by tel-
ephone.
The focus groups are led by members of the study team
after receiving training from an experienced qualitative
researcher, IC. The focus groups are recorded and tran-
scribed verbatim before IC undertakes more detailed anal-
ysis. The analysis will utilise the 'framework' approach
developed at the National Centre for Social Research and
now a widely used method for analysis within the field of
health and social care research [42]. The emergent themes
will be discussed with the study team. Focus groups will
be continued until thematic saturation is reached.
Economic evaluation
The Health Foundation is providing expert health eco-
nomic consultancy to the quality improvement projects.
Once our first-round data collection is complete, we will
review this with the expert advisors [43].
Sample size
Cluster randomised trial sample size
SK, an experienced medical statistician with specific exper-
tise in cluster randomised trial design [44,45], conducted
a sample size calculation taking into account variation
between practices. The study is powered to detect a >3
mmHg difference in systolic BP between the groups over
the two-year duration of the study. Because of the large
number of patients per cluster, the sample size can be esti-
mated using a 'summary statistic' approach whereby each
practice provides a single mean BP. Using a sample dataset
of 30 practices, we have estimated that the variation
between practice means has a standard deviation (SD) of
3.77 mmHg. Assuming that this sample of 30 practices is
representative of the study practices in terms of their size
and number of CKD patients, a sample size of 25 practicesImplementation Science 2009, 4:39 http://www.implementationscience.com/content/4/1/39
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per intervention group will be required to detect a differ-
ence of 3 mmHg at the 5% level with a power of 80%.
The intra-cluster correlation coefficient (ICC) is estimated
to be approximately 0.03. There are likely to be approxi-
mately 500 patients (m) with CKD per practice (based on
a disease prevalence of 6.5%). We can use this informa-
tion to calculate the design effect. The design effect or
inflation factor is the extent to which likely correlation
with a cluster (in our case an individual practice)
increased the sample size required.
A larger difference of clinical importance (e.g., 5 mmHg)
would require a smaller sample. However, given the pop-
ulation nature of this intervention, we decided to be pru-
dent and power the study for a small difference.
Questionnaire survey
A sample of 10 practices in three arms should enable us to
compare changes in confidence in managing CKD. We
expect to recruit practices with a mean practice list size of
around 8,000 [46]. The latest workload survey suggested
that 62% of GPs work full time [47]. There is approxi-
mately one GP per 1,700 patients. The confidence ques-
tionnaire adopts a five-point scale.
We estimate that there will be at least two practice nurses
per 8,000 patients engaged in assessment of cardiovascu-
lar risk including management of CKD. We estimate an
average of 10 practitioners per practice are eligible to com-
plete the questionnaire and that we will achieve a >60%
response rate, or 180 returned questionnaires.
A pilot study as part of the development of the question-
naire shows that the responses have a mean score of two,
and standard deviation of about 1.26. We want to have a
power of 0.80, or equivalently, the probability of a Type II
error of 0.20, the sample size needed to show a change of
0.5 units in the five-point scale, the smallest individual
change meaningful for the study, is 33 practitioners in
each arm of the study.
Stopping rules
Although negative effects are unlikely, any suspected neg-
ative effects will be investigated and the study suspended,
pending review. The principal safety monitoring activities
will be: the observation for falls in people newly started
on additional BP lowering drugs; and to identify whether
there is any relationship between systolic BP and rate of
falls.
Randomisation
Randomisation was conducted in blocks
Practices agree to participate in the study the basis that
they will be assigned at random to an arm of the study. We
excluded practices who wanted to choose an arm of the
study. They are assigned their arm by simple random allo-
cation. Randomisation will be performed with a table of
random numbers by JvV; in the order practices complete
their consent to participate. He allocates, at random,
recruited practices in blocks of nine; accepting that there
will be a final block of less than nine.
Allocation concealment
The allocation is not shared with those who will be
involved in the data analysis. The clinical data collected
are identical in all three arms of the study, so there should
be no clues within these data as to which arm is which.
The allocated arm is recorded in our database of practice
details that is kept entirely separately from the pseudo-
nymised table of data used for analysis. Within the analy-
sis table the practices in each of the three arms are
identifiable for analysis – but there is no labelling of
which specific arm any practice is allocated to. Similarly,
patient and practice identifiers are pseudonymised, which
again makes it harder for the analysts to identify individ-
ual arms.
Ten practices in each arm are labelled as having had the
questionnaire. The four in-depth process evaluation prac-
tices have a separate series of identification numbers so
that they can have their data analysed but excluded from
the study.
Blinding
The field team are aware of which practices are in which
arm, because they must mail or invite participants to the
relevant intervention. However, patient and practice
details are pseudonymised. All cleaning and processing of
data are carried out on the whole database (i.e., all three
arms) simultaneously. We will do this by only revealing
the arm allocation variable at the end of the study. We try
to minimise access to signature data that would allow the
arms of the study to be differentiated. (e.g., if an analyst
knew the precise list size of one practice in the study.)
However, we only plan to reveal this variable when it is
needed for final comparison between arms.
Statistical analysis
Processed data extracted from GP practices and survey
data using questionnaires will be imported onto the SPSS
or a compatible software system. The data analysis will be
conducted in three stages:
Design effect m ICC =+ −
=+ −
=
11
1 500 1 0 03
16
() *
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Univariate and bi-variate analyses
1. We will document the recorded prevalence of CKD, as
defined by socio-demographic (e.g., age, gender, ethnicity,
deprivation scores).
2. We will document the level of confidence of primary
care practitioners in the management of CKD stage three
to five as defined by age, role, and the characteristics of the
GP practices.
3. We will compare the recorded management of CKD
Stage 3 – 5 in the participating GP practices with national
and local guidelines.
4. We will document the recorded key co-morbidities of
CKD stage three to five (e.g., diabetes, ischaemic heart dis-
ease etc).
5. We will compare the recorded management of key co-
morbidities in the participating GP practices with national
and local guidelines.
6. We will document the association between manage-
ment of CKD using BP medication and falls.
Multivariate techniques
1. Using analysis of variance (ANOVA) models, compare
the mean systolic BP of people with CKD stage three to
five in the three arms of the study, before and after the
interventions – the primary outcome measure of this
study
2. Using ANOVA models, compare the confidence level of
primary care practitioners in the management of people
with CKD Stage three to five in the three arms of the study,
before and after the interventions
3. Using multiple regression analyses, explore and quan-
tify relations between independent variables (e.g., known
demographics and risk factors, such as smoking status,
level of cholesterol, obesity, anaemia and alcohol con-
sumption) and dependent variables (e.g., CKD stage three
to five, and diabetes).
Longitudinal data analyses
The temporal dimension of the recorded clinical data col-
lected contemporarily offers an opportunity for analyses
of the natural history and the disease course of CKD. The
data have an advantage of being free from bias from retro-
spective recall, and allow the follow-up of the full spec-
trum of the impact of contributory risk factors on and
outcomes for people with CKD. A particular interest is the
association between management of CKD, the rate of
change of eGFR, falls, and the outcomes of CKD.
Discussion
This study fills a gap in the literature about how to
improve the management of CKD in primary care. This
gap is worth filling, because interventions that can be
administered in primary care should be able to slow the
progression of CKD, and consequently reduce cardiovas-
cular co-morbidity and the need for dialysis and trans-
plantation.
The study is a pragmatic approach to quality improve-
ment (QI) in CKD, and is intended to inform practitioners
and the commissioners of care about the cost effectiveness
of GaP and ABE in this disease area.
The ethical oversight of quality improvement projects
remains a subject of much debate [48]. The study does not
mandate any new intervention to be given to patients in
participating practices, but rather promotes the imple-
mentation of best practice. Personalised decisions to treat
patients will be made by individual practitioners in part-
nership with their patients, as now. Indeed, the primary
research participants of the study are the participating
practitioners rather than they patients they treat. This dis-
tinction has been recognised by the ethics committee that
approved the study; our view is that studies of this poten-
tial size and impact should be part of the ethical approval
process. Strictly, it is only the inclusion of randomisation
which meant that this study required UK research ethics
approval.
There are some weaknesses in the selection of BP as the
primary endpoint; however these effects should be the
same in each arm of the study. GPs will commonly check
BP a second time if it is raised, but not if it is normal.
There can consequently be a tendency for regression
towards the mean in people with raised BP that is greater
than in those with normal BP. This effect will need to be
taken into account in the interpretation of the results. It is
possible that people with raised BP will be under-
detected.
A further problem with BP is that it tends to be recorded
in primary care with marked end digit preference (EDP);
i.e., a preference for recording a zero or five as the terminal
digit [49]. EDP can make BP measurement a very blunt
instrument, and make it harder to detect change.
Although there has been improvement (i.e., a reduction)
in EDP, especially in people with raised BP or cardiovas-
cular co-morbidities, this remains a significant problem.
Although, likely to influence each arm equally, EDP
reduces the fidelity of our observations.
Routinely collected data are not like trial data; they are
recorded inconsistently and reflect the primary healthcare
professional's understanding of the problems presented.Implementation Science 2009, 4:39 http://www.implementationscience.com/content/4/1/39
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The record entries are made within the context of a short
primary care consultation; what is recorded in the record
is not a neutral act and often has connotations for patients
(e.g., 'You told me my kidney blood tests are OK but you
have labelled me as having CKD') [50]. We are only
extracting coded data, and will not have access to free text
data where other key data my lie. For example, 'urine
NAD' (NAD = no abnormality detected) – a negative urine
stick test may be recorded in the records; but as it has not
been coded this test will remain hidden. Similarly, hospi-
tal letters and reports where the text has not been coded
will also remain invisible to our searches.
Some members of the project team have been involved in
the development of ABE as a quality improvement inter-
vention for some time (SdeL, TC, JvV, NH) [19-21]. How-
ever, we have no personal stake that we feel will bias the
outcome of this trial, and building-in independent scru-
tiny of the data should help ensure this is a fair test.
There are also a number of external pressures that are
influencing the study; the most important are QOF CKD
Indicator [51] and NICE guidance [4] issued in September
2008. The CKD QOF indicator is progressively being
aligned with NICE guidance; and it is possible that these
influences may be greater than any effect from the study.
However, these are also factors which will equally influ-
ence all three arms of the study.
Conclusion
This study should provide useful information about the
influence of straightforward quality improvement inter-
ventions on the management of CKD; and if they are addi-
tive on the influences of financially incentivised QOF and
the new national guidelines (NICE). The study will face all
the challenges associated with working with routinely col-
lected data, as well as the many confounding factors. We
anticipate reporting whether the QI interventions tested
have a place in improving the management of CKD.
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Appendix 1
Themes to be explored in the first year of the study
1. Prevalence. Prevalence of CKD, and prevalence by age
band, for each of stage three to five CKD.
1.1 Practice prevalence (from serum creatinine
records) compared with:
1.2 Population prevalence (from literature)
1.3 QOF prevalence (based on business case rules)
1.4 Standardised prevalence; deprivation and ethnic-
ity recording
2.  Proteinuria recording. Proportion of CKD patients
with proteinuria estimation separately in diabetics and
non-diabetics. Proportion of patients in whom proteinu-
ria has been measured with albumin: creatinine ratio
(ACR)>30 and >70 mg/mmol in non diabetics.
3. BP. Indicators of BP control.
3.1 Number of measurement in last 12 months
3.2 Most recent systolic and diastolic BPImplementation Science 2009, 4:39 http://www.implementationscience.com/content/4/1/39
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3.3 Mean systolic and diastolic in last 6 months
3.4 Proportion meeting QOF standard, and NICE tar-
gets
4.  Angiotensin blockade in CKD. Use of angiotensin
modulating drugs (ACEI and ARB)
4.1 Total number of prescriptions
4.2 Use in CKD with proteinuria
4.3 Exemption coding
5. Cardiovascular co-morbidities. Prevalence, use of 10
year risk scoring.
6. Process of delivering care. Hints, tips, case-studies of
how to achieve change (e.g., All hypertensives and those
with CVS co-morbidity have a proteinuria test when hav-
ing their blood tests.). Which primary care professionals
are involved? Shift to primary care management.
7. Motivation to change care. Is CKD an illness? Are we
inappropriately labelling much of the elderly population?
Do the biomedical interventions do more good than
harm?
8. Improving the intervention. How could the interven-
tion be improved?
Appendix 2
Themes for exploration in year two
1. Programme fidelity and intervention exposure. Has
the implementation been feasible (programme fidelity)
and what proportion of the practice have been interested
in the feedback and results (intervention exposure)?
2. How can the QI interventions be improved? Sug-
gested improvements to the interventions.
3. Diabetes and CKD. Prevalence of Diabetes and CKD
and quality of management (comparing quality of man-
agement with QOF and national guidance, including new
NICE guidance).
3.1 BP recording and control and use of angiotensin
modulating drugs
3.2 HbA1c recording and value (compared with non-
CKD diabetics, controlling for age and gender)
3.3 ACR (Albumin Creatinine ratio) in people with
diabetes with CKD
3.4 Lipid management and use of statins and other
medications for 1° and 2° prevention
3.5 Use of aspirin as primary and secondary preven-
tion
4. Cardiovascular co-morbidity. We will look at risk fac-
tor management in people with cardiovascular disease, to
include: use of lipid lowering therapy; use of aspirin;
smoking cessation.
5.  Progression of CKD. We will identify people with
rapid progression.
6. Anaemia and CKD. We will flag people with anaemia
who cross current NICE thresholds
7. Avoiding harm. We will look specifically for any evi-
dence of increased numbers of falls; but are open to other
unanticipated harmful consequences of the intervention.
8. Good ideas. The workshops will also seek to capture
any examples of good practice and disseminate them
across the group.
9. Process of delivering care. Any issues of call/recall of
patients and concordance with therapy – especially angi-
otensin modulating drugs will be explored.
10. Unexpected consequences. We will try to identify any
unexpected consequences of the interventions; good or
bad.
Appendix 3
Overview of the dataset extracted
Practice data
List size
QOF performance
Number and range of practice members engaged in CKD
management
Pseudonymised practice indicator
Demographic
Age, gender
Ethnicity
Postcode (only first part is retained)Implementation Science 2009, 4:39 http://www.implementationscience.com/content/4/1/39
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Index of deprivation (calculated in each practice from the
postcode which is then deleted)
Cause of death & death
Clinical and laboratory
Serial measures of BP
Serial measures of serum creatinine concentration and
eGFR
Co-morbid conditions (diabetes and its complications,
ischaemic heart disease, heart failure, urinary obstruction)
Cardiovascular risk factors: smoking status; serum choles-
terol and total cholesterol: HDL ratio; BMI, alcohol con-
sumption; glycated haemoglobin and microalbuminuria
in people with diabetes mellitus; urinalysis and total pro-
tein creatinine ratio; haemoglobin concentration
Lower urinary tract symptoms, prostate disease and uro-
logical factors which may reduce eGFR
Falls dataset (falls, likely fragility fractures, new diagnosis
of osteoporosis)
Medications for optimal management that also impair
renal function
Referral (to renal, diabetes, care of the elderly, urological
and other specialties)
Other
Number of consultations in primary care
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